Dosage and administration of dasatinib/tasatinib

Dasatinib treatment should be carried out under the guidance of doctors with experience in the diagnosis and treatment of leukemia. As a highly selective tyrosine kinase inhibitor, its dosage design needs to be individually adjusted based on patient type, disease course, and weight. For adult patients with chronic phase chronic myeloid leukemia (CML), the recommended starting dose is 100 mg, taken orally once a day; for patients with accelerated phase CML, myeloid or lymphoblastic phase CML, and Ph+acute lymphoblastic leukemia (ALL), the recommended starting dose is 140 mg, taken orally once a day. The drug can be taken at any time in the morning or evening, with or without food, but the tablet should be swallowed whole and avoid crushing or chewing to ensure a stable release profile of the drug.

In pediatric patients, dosage needs to be adjusted according to weight class. For those weighing 10-20kg, 40mg per day, for those 20-30kg, 60mg per day, for those 30-45kg, 70mg per day, and for those ≥45kg, 100mg per day. As body weight changes, it is recommended to reassess dosage every three months to maintain stable pharmacokinetic exposure.

It should be noted during treatment that dasatinib may cause side effects such as thrombocytopenia, leukopenia, or pleural effusion. Therefore, regular blood picture and chest X-ray monitoring are very important. For patients who experience adverse reactions, the medication can be temporarily discontinued or the dosage reduced under the guidance of a doctor to balance efficacy and safety.

The treatment cycle of dasatinib is long, so you need to take the medication regularly to avoid missing doses. If a dose is missed, the dose should be taken as soon as possible on the same day, but the dose should not be repeated within a short period of time. Clinical data show that regular use of dasatinib can significantly delay disease progression and improve the complete molecular response rate.

Overall, the indications for satinib cover multi-stage leukemia treatment from new diagnosis to drug-resistant relapse. Standardized dose management is the key to ensuring efficacy and safety, and is also an important basis for maintaining long-term remission.

Reference materials:https://go.drugbank.com/drugs/DB01254